Evidence map›Paper›PMID 42057349›Full record

ReviewCancer biology & medicine2026

Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications.

Chuxiong Cheng, Jingsong Wang, Jin Xie, Hanlin Yin, Zhihang Xu, Yuqi Xie, Taochen He, Zhenlai Jiang, Yu Wang, Wenchuan Wu and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chuxiong Cheng *Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jingsong Wang *Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jin Xie *Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Hanlin YinDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhihang XuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yuqi XieDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Taochen HeDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhenlai JiangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yu WangDepartment of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Wenchuan WuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wenhui LouDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jie WangDepartment of Chinese Medicine & Integrative Medicine, Shanghai Geriatric Medical Center, Zhongshan Hospital, Fudan University, Shanghai 201104, China.ORCID 0000-0002-9097-7864
Liang LiuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0000-0002-7826-3877
Ning PuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0000-0002-3123-493X

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-2022METAZQN-0003Beijing Xisike Clinical Oncology Research Foundation Y-Gilead2024-PT-0002Beijing Xisike Clinical Oncology Research Foundation Y-HR2022MS-0251Liu Liang Expert Workstation of Yunnan Province 202305AF150148National Natural Science Foundation of China 82273382National Natural Science Foundation of China 82473459National Natural Science Foundation of China 82503105National Natural Science Foundation of China 82572967Program of Shanghai Academic/Technology Research Leader 23XD1400600Shanghai Anticancer Association EYAS PROJECT SACA-CY24B09Shanghai Municipal Health Commission Scientific Research Project 201940019Shanghai Municipal Health Commission Scientific Research Project 20244Y0023Shanghai Municipal Health Commission Scientific Research Project 20254Y0181Shanghai "Rising Stars of Medical Talents" Youth Development Program, the Clinical Research of Zhongshan Hospital ZSLCYJ202329Shanghai Science and Technology Commission Innovative Pharmaceutical Products Application Demonstration Project 24SF1900300
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies of the digestive system, with a 5-year survival rate of only 13%, which is largely due to late-stage diagnosis and limited therapeutic options. Emerging evidence indicates that the gut microbiota has a critical role in PDAC tumorigenesis, progression, and therapeutic response. This review comprehensively summarizes current insights into gut microbiota-PDAC interactions, highlighting microbial alterations across taxonomic, functional, and clinical dimensions. Gut dysbiosis, which is marked by depletion of beneficial species and enrichment of pathogenic taxa, contributes to carcinogenesis through chronic inflammation, immune dysregulation, and metabolic reprogramming. In particular, the loss of butyrate-producing bacteria reduces anti-inflammatory activity and weakens CD8

Indexed as

CarcinogenesisCarcinoma, Pancreatic DuctalGastrointestinal MicrobiomePancreatic NeoplasmsAnimalsDisease ProgressionDysbiosisHumansTumor MicroenvironmentbiomarkerGut microbiotamicrobiota-targeted therapypancreatic cancertumorigenesistumor microenvironment

Identifiers

PMID42057349
PMCPMC13244306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.